Interview: Immunocore Gets Ready To Go To Market

The first molecule from its collaboration with GSK has just gone into Phase I trials but Immunocore CEO Andrew Hotchkiss tells Scrip that the UK biotech unicorn is also preparing for the launch of its own lead candidate, IMCgp100 for uveal melanoma.

Sprinting
Immunocore and GSK trial gets started • Source: Shutterstock

Immunocore Ltd., long-time research star of the UK biotech sector, is in a period of major transition as its development and commercialization plans begin to take shape.

So said CEO AndrewHotchkiss in an interview with Scrip ahead of the news announced Aug. 20 that the first potential...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

More from Anticancer